FACTBOX: Largest biotechnology deals in 2007

(Reuters) - Biotechnology company Biogen Idec Inc. (BIIB.O) on Friday had put itself up for sale after receiving expressions of interest from parties including billionaire financier Carl Icahn. Investors speculated on Monday that biotech companies such as Genzyme Corp. (GENZ.O) could be targeted next.

Below is a list of the largest global biotechnology deals this year, according to research firm Dealogic. BUYER TARGET COMPANY DEAL VALUE AstraZeneca Plc MedImmune Inc. $14.9 billion Schering-Plough Corp. Organon BioSciences NV $14.4 billion Mylan Laboratories Merck KGaA (generic drug unit) $6.6 billion Novator Actavis Group (61.5 pct stake) $4.5 billion Tanabe Seiyaku Co. Mitsubishi Pharma Corp. $3.8 billion SOURCE: Dealogic